JP2025504219A - Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ - Google Patents

Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ Download PDF

Info

Publication number
JP2025504219A
JP2025504219A JP2024547249A JP2024547249A JP2025504219A JP 2025504219 A JP2025504219 A JP 2025504219A JP 2024547249 A JP2024547249 A JP 2024547249A JP 2024547249 A JP2024547249 A JP 2024547249A JP 2025504219 A JP2025504219 A JP 2025504219A
Authority
JP
Japan
Prior art keywords
approximately
combination
arginine
pharmaceutical combination
sildenafil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504219A5 (https=
Inventor
ウェイ チャオ，ミン
ハン リン，チン
トン チェン，ポー
Original Assignee
フューチャー ファーマテック インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フューチャー ファーマテック インコーポレーテッド filed Critical フューチャー ファーマテック インコーポレーテッド
Publication of JP2025504219A publication Critical patent/JP2025504219A/ja
Publication of JP2025504219A5 publication Critical patent/JP2025504219A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024547249A 2022-02-09 2023-02-09 Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ Pending JP2025504219A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TW111104639A TWI859506B (zh) 2022-02-09 2022-02-09 化合物組合用於製作血管疾病治療藥的用途
TW111104639 2022-02-09
PCT/GB2023/050296 WO2023152500A1 (en) 2022-02-09 2023-02-09 Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine

Publications (2)

Publication Number Publication Date
JP2025504219A true JP2025504219A (ja) 2025-02-06
JP2025504219A5 JP2025504219A5 (https=) 2026-02-13

Family

ID=85283927

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547249A Pending JP2025504219A (ja) 2022-02-09 2023-02-09 Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ

Country Status (8)

Country Link
US (1) US20250134892A1 (https=)
EP (1) EP4475833A1 (https=)
JP (1) JP2025504219A (https=)
KR (1) KR20240146018A (https=)
CN (1) CN116808224A (https=)
AU (1) AU2023219232A1 (https=)
TW (1) TWI859506B (https=)
WO (1) WO2023152500A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025046207A1 (en) * 2023-08-31 2025-03-06 Future Pharmtech Inc. New use of a pde 5 inhibitor combination in promoting neurite outgrowth
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4699299A (en) 1998-06-26 2000-01-17 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
IL132460A0 (en) * 1999-10-19 2001-03-19 Laniado Shlomo Sildenafil preparation

Also Published As

Publication number Publication date
CN116808224A (zh) 2023-09-29
US20250134892A1 (en) 2025-05-01
TW202332450A (zh) 2023-08-16
AU2023219232A1 (en) 2024-07-25
WO2023152500A1 (en) 2023-08-17
EP4475833A1 (en) 2024-12-18
KR20240146018A (ko) 2024-10-07
TWI859506B (zh) 2024-10-21

Similar Documents

Publication Publication Date Title
KR100849999B1 (ko) 두통, 편두통, 구역질 및 구토를 위한 약학적 조성물
Angulo et al. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF
AU2013259526B2 (en) New methods
JP2025504219A (ja) Ｐｄｅ５阻害剤、アルギニン、及びｎ－アセチルシステインを含む、血管疾患を治療するための化合物の組合せ
US20230115611A1 (en) Treatment of pain and vasoconstriction
CN112654264A (zh) 使用至少一种甘氨酸或其衍生物、至少一种n-乙酰半胱氨酸或其衍生物和至少一种烟酰胺核糖核苷或nad+前体的组合物和方法
RU2336870C2 (ru) Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта
JP2024133735A (ja) Ｉｖ型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
RU2426535C2 (ru) Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
JP2014527506A (ja) 糖尿病治療のための組み合わせ
Chen et al. Drug-drug interaction between paxlovid and tacrolimus in a patient with myasthenia gravis and SARS-CoV-2 infection
WO2025026900A1 (en) Compounds for the treatment or prevention of gout
JPH06500537A (ja) アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
EP3562485B1 (en) Non-hormonal compositions and methods for male contraception comprising (r)-silodosin
US20210128596A1 (en) Compositions and methods for treating septic cardiomyopathy
NL2036681B1 (en) Application of Naringin Combined with Rapamycin in the Preparation of Medications for Treating Hyperlipidemia
US20060194810A1 (en) Methods of treating ischemic related conditions
KR20140147799A (ko) 독성유발기 및 n-아세틸-l-시스테인 중 적어도 어느 하나를 포함하는 의약품을 포함하는 약학조성물
Imperial Effect of Aspalathus linearis supplementation, during anti-retroviral treatment, on the heart and aortas of male Wistar rats and the effects of drinking rooibos on the cardiovascular profile of patients on ART.
Vare et al. Evaluation of antiulcer activity of diltiazem in rats
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
WO2024177104A1 (ja) 末梢神経障害の治療又は予防のための医薬
HK40041318A (en) Non-hormonal methods for male contraception comprising (r)-silodosin
HK40041318B (en) Non-hormonal methods for male contraception comprising (r)-silodosin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240925

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260203